PT  - JOURNAL ARTICLE
AU  - Molteni, Erika
AU  - Sudre, Carole H.
AU  - Canas, Liane S.
AU  - Bhopal, Sunil S.
AU  - Hughes, Robert C.
AU  - Chen, Liyuan
AU  - Deng, Jie
AU  - Murray, Benjamin
AU  - Kerfoot, Eric
AU  - Antonelli, Michela
AU  - Graham, Mark
AU  - Kläser, Kerstin
AU  - May, Anna
AU  - Hu, Christina
AU  - Pujol, Joan Capdevila
AU  - Wolf, Jonathan
AU  - Hammers, Alexander
AU  - Spector, Tim D.
AU  - Ourselin, Sebastien
AU  - Modat, Marc
AU  - Steves, Claire J.
AU  - Absoud, Michael
AU  - Duncan, Emma L.
TI  - Illness characteristics of COVID-19 in children infected with the SARS-CoV-2 Delta variant
AID  - 10.1101/2021.10.06.21264467
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.06.21264467
4099  - http://medrxiv.org/content/early/2021/10/07/2021.10.06.21264467.short
4100  - http://medrxiv.org/content/early/2021/10/07/2021.10.06.21264467.full
AB  - Background The Delta (B.1.617.2) SARS-CoV-2 variant became the predominant UK circulating strain in May 2021. Whether COVID-19 from Delta infection differs to infection with other variants in children is unknown.Methods Through the prospective COVID Symptom Study, 109,626 UK school-aged children were proxy-reported between December 28, 2020 and July 8, 2021. We selected all symptomatic children who tested positive for SARS-CoV-2 and were proxy-reported at least weekly, within two timeframes: December 28, 2020 to May 6, 2021 (Alpha (B.1.1.7) the main UK circulating variant); and May 26 to July 8, 2021 (Delta the main UK circulating variant). We assessed illness profiles (symptom prevalence, duration, and burden), hospital presentation, and presence of long (≥28 day) illness; and calculated odds ratios for symptoms presenting within the first 28 days of illness.Findings 694 (276 younger [5-11 years], 418 older [12-17 years]) symptomatic children tested positive for SARS-CoV-2 with Alpha infection and 706 (227 younger and 479 older) children with Delta infection. Median illness duration was short with either variant (overall cohort: 5 days (IQR 2–9.75) with Alpha, 5 days (IQR 2-9) with Delta). The seven most prevalent symptoms were common to both variants. Symptom burden over the first 28 days was slightly greater with Delta compared with Alpha infection (in younger children, 3 (IQR 2–5) with Alpha, 4 (IQR 2–7) with Delta; in older children 5 (IQR 3–8) with Alpha and 6 (IQR 3–9) with Delta infection in older children). The odds of several symptoms were higher with Delta than Alpha infection, including headache and fever. Few children presented to hospital, and long illness duration was uncommon, with either variant.Interpretation COVID-19 in UK school-aged children due to SARS-CoV-2 Delta strain B.1.617.2 resembles illness due to the Alpha variant B.1.1.7., with short duration and similar symptom burden.Funding ZOE Limited, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation and Alzheimer’s Society.Ethics Ethics approval was granted by KCL Ethics Committee (reference LRS-19/20-18210).Evidence before this study To identify existing evidence for differences in COVID-19 due to infection with Alpha (B.1.1.7) or Delta (B.1.617.2) SARS-CoV-2 variants, we searched PubMed for peer-reviewed articles and medRxiv for preprint publications between March 1, and September 17, 2021 using keywords (“SARS-CoV-2” OR “COVID-19”) AND (children OR p?ediatric*) AND (“delta variant” OR “B.1.617.2”). We did not restrict our search by language. Of twenty published articles identified in PubMed, we found one case study describing disease presentation associated with Delta variant infection in a child. Another study examining the increase in hospitalization rates of paediatric cases in USA from August 1, 2020 to August 27, 2021 stated that “It is not known whether the B.1.617.2 (Delta) variant […] causes different clinical outcomes in children and adolescents compared with variants that circulated earlier.” Four studies reported cases of transmission of the Delta variant in school and community contexts; and two discussed screening testing in school-aged children (thus not directly relevant to the research question here). Remaining papers did not target paediatric age specifically. We found no studies investigating differences in COVID-19 presentation (e.g., duration, burden, individual symptoms) in school-aged children either in the UK or world-wide.Added value of this study We describe and compare illness profiles in symptomatic UK school-aged children (aged 5–17 years) with COVID-19 when either Alpha or Delta strains were the predominant circulating SARS-CoV-2 variant. Our data, collected through one of the largest UK citizen science epidemiological initiatives, show that symptom profile and illness duration of COVID-19 are broadly similar between the strains. Although there were slightly more symptoms with Delta than with Alpha, particularly in older children, this was offset by similar symptom duration (whether considered for symptoms individually or for illness overall). Our study adds quantitative information to the debate on whether there are meaningful clinical differences in COVID-19 due to Alpha vs. Delta variants; and contributes to the discussion regarding rationale for vaccinating children (particularly younger children) against SARS-CoV-2.Implications of all the available evidence Our data confirm that COVID-19 in UK school-aged children is usually of short duration and similar symptom burden, whether due to Delta or Alpha. Our data contribute to epidemiological surveillance from the wider UK population, and we capture common and generally mild paediatric presentations of COVID-19 that might be missed using clinician-based surveillance alone. Our data will also be useful for the vaccination debate.Competing Interest StatementTim D. Spector reports being a consultant for Zoe Limited, during the conduct of the study. Anna May, Christina Hu, Joan Capdevila Pujol, and Jonathan Wolf are employed at ZOE Limited, UK.Clinical TrialThis is not a clinical trialFunding StatementZOE Limited, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation and Alzheimers Society.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was granted by KCL Ethics Committee (reference LRS-19/20-18210).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData collected in the ZOE COVID Study App can be shared with other health researchers through the UK National Health Service-funded Health Data Research UK and Secure Anonymised Information Linkage consortium, housed in the UK Secure Research Platform (Swansea, UK). Anonymised data are available to be shared with researchers according to their protocols in the public interest https://web.www.healthdatagateway.org/dataset/594cfe55-96e3-45ff-874c-2c0006eeb881. https://arxiv.org/abs/2011.00867 CIConfidence IntervalCOVID-19coronavirus disease 2019FDRFalse discovery rateIQRinter-quartile rangeKCLKing’s College LondonLFATLateral flow antigen testONSOffice for National Statistics (UK)PCRpolymerase chain reactionSARS-CoV-2severe acute respiratory syndrome-related coronavirus 2UKUnited Kingdom of Great Britain and Northern IrelandUSAUnited States of AmericaWHOWorld Health Organization